EUVIMEDEUVIMED entdecken
Crossref

Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma

Marianne Baastrup Soendergaard iD, Susanne Hansen, Kjell Erik Julius Håkansson iD, Anna von Bülow, Anne-Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen Bertelsen, Niels Steen Krogh, Ole Hilberg und 2 weitere

Allergy · 2025

DOI: 10.1111/all.16425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Marianne Baastrup Soendergaard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Asthma, Nitric Oxide, Biological Products, Interleukin-5. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: DSAR is funded by grants from GlaxoSmithKline, Novartis, AstraZeneca, Teva and Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes.

Methods

We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease.

Results

We identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function.

Conclusions

FeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaNitric OxideBiological ProductsInterleukin-5Anti-Asthmatic AgentsHumansMaleFemaleMiddle AgedSeverity of Illness IndexAdultRemission InductionTreatment OutcomeFractional Exhaled Nitric Oxide TestingAgedBiomarkersRegistries

Stichwörter der Autor:innen

asthmabiologicsbiomarkers

Substanzen

Nitric OxideBiological ProductsInterleukin-5Anti-Asthmatic AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.
  • Centre for Clinical Research and Prevention, Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.
  • Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
  • Allergy Clinic, Gentofte University Hospital, Hellerup, Denmark.

ORCID-Profile: Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Celeste Porsbjerg

Förderung

  • DSAR is funded by grants from GlaxoSmithKline, Novartis, AstraZeneca, Teva and Sanofi

Zitieren

APA

Soendergaard, M. B., Hansen, S., Håkansson, K. E. J., von Bülow, A., Bjerrum, A. S., Schmid, J. M., Johansson, S. L., Rasmussen, L. M., Johnsen, C. R., Bertelsen, B. B., Krogh, N. S., Hilberg, O., Ulrik, C. S., & Porsbjerg, C. (2025). Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma. Allergy. https://doi.org/10.1111/all.16425

Vancouver

Soendergaard MB, Hansen S, Håkansson KEJ, von Bülow A, Bjerrum AS, Schmid JM, et al. Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma. Allergy. 2025. doi:10.1111/all.16425

BibTeX
@article{Soendergaard2025,
  author = {Soendergaard, Marianne Baastrup and Hansen, Susanne and Håkansson, Kjell Erik Julius and von Bülow, Anna and Bjerrum, Anne-Sofie and Schmid, Johannes Martin and Johansson, Sofie Lock and Rasmussen, Linda Makowska and Johnsen, Claus Rikard and Bertelsen, Barbara Bonnesen and Krogh, Niels Steen and Hilberg, Ole and Ulrik, Charlotte Suppli and Porsbjerg, Celeste},
  title = {Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16425}
}
Kostenlos starten →